Interdisziplinäre Früherkennung, Diagnostik, Therapie und Nachsorge des Mammakarzinoms. Leitlinie der DGGG und DKG (S3-Level, AWMF-Registernummer 032/045OL, Dezember 2017) – Teil 2 mit Empfehlungen zur Therapie des primären, rezidivierten und fortgeschrittenen Mammakarzinoms

Zusammenfassung

Ziele Das Ziel dieser offiziellen Leitlinie, die von der Deutschen Gesellschaft für Gynäkologie und Geburtshilfe (DGGG) und der Deutschen Krebsgesellschaft (DKG) publiziert und koordiniert wurde, ist es, die Früherkennung, Diagnostik, Therapie und Nachsorge des Mammakarzinoms zu optimieren.

Methode Der Aktualisierungsprozess der S3-Leitlinie aus 2012 basierte zum einen auf der Adaptation identifizierter Quellleitlinien und zum anderen auf Evidenzübersichten, die nach Entwicklung von PICO-Fragen (PICO: Patients/Interventions/Control/Outcome), systematischer Recherche in Literaturdatenbanken sowie Selektion und Bewertung der gefundenen Literatur angefertigt wurden. In den interdisziplinären Arbeitsgruppen wurden auf dieser Grundlage Vorschläge für Empfehlungen – und Statements erarbeitet, die im Rahmen von strukturierten Konsensusverfahren modifiziert und graduiert wurden.

Empfehlungen Teil 2 dieser Kurzversion der Leitlinie zeigt Empfehlungen zur Therapie des primären, rezidivierten und metastasierten Mammakarzinoms: Die lokoregionären Therapien erfahren in der aktuellen Leitlinie eine Deeskalation. Neben einer Verringerung des Sicherheitsabstandes bei den operativen Verfahren gibt die Leitlinie auch Empfehlungen zu einer reduzierten Radikalität bei axillären Interventionen. Die Systemtherapie richtet sich nach den tumorbiologischen Eigenschaften, neue Substanzen stehen insbesondere beim metastatierten Mammakarzinom zur Verfügung.

Schlüsselwörter

Brustkrebs - Leitlinie - Therapie - primäres Mammakarzinom - metastasiertes Mammakarzinom

• References/Literatur

• 1 Moran MS, Schnitt SJ, Giuliano AE. et al. Society of Surgical Oncology-American Society for Radiation Oncology consensus guideline on margins for breast-conserving surgery with whole-breast irradiation in stages I and II invasive breast cancer. J Clin Oncol 2014; 32: 1507-1515
• 2 Department of Health. Diagnosis, staging and treatment of patients with breast cancer. National Clinical Guideline No. 7. June 2015. ISSN 2009-6259. Online: https://www.hse.ie/eng/services/list/5/cancer/profinfo/guidelines/breast/ last access: May 2016
• 3 Houssami N, Macaskill P, Marinovich ML. et al. The association of surgical margins and local recurrence in women with early-stage invasive breast cancer treated with breast-conserving therapy: a meta-analysis. Ann Surg Oncol 2014; 21: 717-730
• 4 Early Breast Cancer Trialistsʼ Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005; 365: 1687-1717
• 5 Fisher B, Anderson S, Tan-Chiu E. et al. Tamoxifen and chemotherapy for axillary node-negative, estrogen receptor-negative breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-23. J Clin Oncol 2001; 19: 931-942
• 6 Veronesi U, Cascinelli N, Mariani L. et al. Twenty-year follow-up of a randomized study comparing breast-conserving surgery with radical mastectomy for early breast cancer. N Engl J Med 2002; 347: 1227-1232
• 7 Fisher B, Anderson S, Bryant J. et al. Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. N Engl J Med 2002; 347: 1233-1241
• 8 Wald NJ, Murphy P, Major P. et al. UKCCCR multicentre randomised controlled trial of one and two view mammography in breast cancer screening. BMJ 1995; 311: 1189-1193
• 9 Weaver DL, Krag DN, Ashikaga T. et al. Pathologic analysis of sentinel and nonsentinel lymph nodes in breast carcinoma: a multicenter study. Cancer 2000; 88: 1099-1107
• 10 McCahill LE, Single RM, Aiello Bowles EJ. et al. Variability in reexcision following breast conservation surgery. JAMA 2012; 307: 467-475
• 11 New Zealand Guidelines Group (NZGG). Management of Early Breast Cancer – Evidence-based Best Practice Guideline. New Zealand Guidelines Group (2009). Online: https://www.health.govt.nz/system/files/documents/publications/mgmt-of-early-breast-cancer-aug09.pdf last access: 01.09.2016
• 12 Fisher B, Anderson S. Conservative surgery for the management of invasive and noninvasive carcinoma of the breast: NSABP trials. National Surgical Adjuvant Breast and Bowel Project. World J Surg 1994; 18: 63-69
• 13 Voogd AC, Nielsen M, Peterse JL. et al. Differences in risk factors for local and distant recurrence after breast-conserving therapy or mastectomy for stage I and II breast cancer: pooled results of two large European randomized trials. J Clin Oncol 2001; 19: 1688-1697
• 14 De La Cruz L, Moody AM, Tappy EE. et al. Overall Survival, Disease-Free Survival, Local Recurrence, and Nipple-Areolar Recurrence in the Setting of Nipple-Sparing Mastectomy: A Meta-Analysis and Systematic Review. Ann Surg Oncol 2015; 22: 3241-3249
• 15 Endara M, Chen D, Verma K. et al. Breast reconstruction following nipple-sparing mastectomy: a systematic review of the literature with pooled analysis. Plast Reconstr Surg 2013; 132: 1043-1054
• 16 Lanitis S, Tekkis PP, Sgourakis G. et al. Comparison of skin-sparing mastectomy versus non-skin-sparing mastectomy for breast cancer: a meta-analysis of observational studies. Ann Surg 2010; 251: 632-639
• 17 Piper M, Peled AW, Foster RD. et al. Total skin-sparing mastectomy: a systematic review of oncologic outcomes and postoperative complications. Ann Plast Surg 2013; 70: 435-437
• 18 Gentilini O, Botteri E, Rotmensz N. et al. Conservative surgery in patients with multifocal/multicentric breast cancer. Breast Cancer Res Treat 2009; 113: 577-583
• 19 Lynch SP, Lei X, Hsu L. et al. Breast cancer multifocality and multicentricity and locoregional recurrence. Oncologist 2013; 18: 1167-1173
• 20 Neri A, Marrelli D, Megha T. et al. Clinical significance of multifocal and multicentric breast cancers and choice of surgical treatment: a retrospective study on a series of 1158 cases. BMC Surg 2015; 15: 1
• 21 Patani N, Carpenter R. Oncological and aesthetic considerations of conservational surgery for multifocal/multicentric breast cancer. Breast J 2010; 16: 222-232
• 22 Shaikh T, Tam TY, Li T. et al. Multifocal and multicentric breast cancer is associated with increased local recurrence regardless of surgery type. Breast J 2015; 21: 121-126
• 23 Tan MP, Sitoh NY, Sim AS. Breast conservation treatment for multifocal and multicentric breast cancers in women with small-volume breast tissue. ANZ J Surg 2017; 87: E5-E10 doi:10.1111/ans.12942
• 24 Wolters R, Wöckel A, Janni W. et al. Comparing the outcome between multicentric and multifocal breast cancer: what is the impact on survival, and is there a role for guideline-adherent adjuvant therapy? A retrospective multicenter cohort study of 8,935 patients. Breast Cancer Res Treat 2013; 142: 579-590
• 25 Yerushalmi R, Tyldesley S, Woods R. et al. Is breast-conserving therapy a safe option for patients with tumor multicentricity and multifocality?. Ann Oncol 2012; 23: 876-881
• 26 Rhiem K, Engel C, Graeser M. et al. The risk of contralateral breast cancer in patients from BRCA1/2 negative high risk families as compared to patients from BRCA1 or BRCA2 positive families: a retrospective cohort study. Breast Cancer Res 2012; 14: R156
• 27 Fayanju OM, Stoll CR, Fowler S. et al. Contralateral prophylactic mastectomy after unilateral breast cancer: a systematic review and meta-analysis. Ann Surg 2014; 260: 1000-1010
• 28 Kurian AW, Lichtensztajn DY, Keegan TH. et al. Use of and mortality after bilateral mastectomy compared with other surgical treatments for breast cancer in California, 1998–2011. JAMA 2014; 312: 902-914
• 29 Potter S, Brigic A, Whiting PF. et al. Reporting clinical outcomes of breast reconstruction: a systematic review. J Natl Cancer Inst 2011; 103: 31-46
• 30 The National Institute for Health and Care Excellence (NICE). Advanced breast cancer: diagnosis and treatment. 2009 [addendum 2014]. Online: https://www.nice.org.uk/guidance/cg81/evidence/addendum-242246990
• 31 Lyman GH, Temin S, Edge SB. et al. Sentinel lymph node biopsy for patients with early-stage breast cancer: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 2014; 32: 1365-1383
• 32 Krag DN, Anderson SJ, Julian TB. et al. Sentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast cancer: overall survival findings from the NSABP B-32 randomised phase 3 trial. Lancet Oncol 2010; 11: 927-933
• 33 Houssami N, Ciatto S, Turner RM. et al. Preoperative ultrasound-guided needle biopsy of axillary nodes in invasive breast cancer: meta-analysis of its accuracy and utility in staging the axilla. Ann Surg 2011; 254: 243-251
• 34 Straver ME, Meijnen P, van Tienhoven G. et al. Role of axillary clearance after a tumor-positive sentinel node in the administration of adjuvant therapy in early breast cancer. J Clin Oncol 2010; 28: 731-737
• 35 Giuliano AE, Hunt KK, Ballman KV. et al. Axillary dissection vs. no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial. JAMA 2011; 305: 569-575
• 36 Galimberti V, Cole BF, Zurrida S. et al. Axillary dissection versus no axillary dissection in patients with sentinel-node micrometastases (IBCSG 23-01): a phase 3 randomised controlled trial. Lancet Oncol 2013; 14: 297-305
• 37 Classe JM, Bordes V, Campion L. et al. Sentinel lymph node biopsy after neoadjuvant chemotherapy for advanced breast cancer: results of Ganglion Sentinelle et Chimiotherapie Neoadjuvante, a French prospective multicentric study. J Clin Oncol 2009; 27: 726-732
• 38 Boughey JC, Suman VJ, Mittendorf EA. et al. Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: the ACOSOG Z1071 (Alliance) clinical trial. JAMA 2013; 310: 1455-1461
• 39 Kuehn T, Bauerfeind I, Fehm T. et al. Sentinel-lymph-node biopsy in patients with breast cancer before and after neoadjuvant chemotherapy (SENTINA): a prospective, multicentre cohort study. Lancet Oncol 2013; 14: 609-618
• 40 Clarke M, Collins R, Darby S. et al. Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005; 366: 2087-2106
• 41 Early Breast Cancer Trialistsʼ Collaborative Group (EBCTCG). Darby S, McGale P, Correa C. et al. Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomised trials. Lancet 2011; 378: 1707-1716
• 42 Pötter R, Gnant M, Kwasny W. et al. Lumpectomy plus tamoxifen or anastrozole with or without whole breast irradiation in women with favorable early breast cancer. Int J Radiat Oncol Biol Phys 2007; 68: 334-340
• 43 Hughes KS, Schnaper LA, Bellon JR. et al. Lumpectomy plus tamoxifen with or without irradiation in women age 70 years or older with early breast cancer: long-term follow-up of CALGB 9343. J Clin Oncol 2013; 31: 2382-2387
• 44 Kunkler IH, Williams LJ, Jack WJ. et al. Breast-conserving surgery with or without irradiation in women aged 65 years or older with early breast cancer (PRIME II): a randomised controlled trial. Lancet Oncol 2015; 16: 266-273
• 45 Blamey RW, Bates T, Chetty U. et al. Radiotherapy or tamoxifen after conserving surgery for breast cancers of excellent prognosis: British Association of Surgical Oncology (BASO) II trial. Eur J Cancer 2013; 49: 2294-2302
• 46 Fyles AW, McCready DR, Manchul LA. et al. Tamoxifen with or without breast irradiation in women 50 years of age or older with early breast cancer. N Engl J Med 2004; 351: 963-970
• 47 Kauer-Dorner D, Pötter R, Resch A. et al. Partial breast irradiation for locally recurrent breast cancer within a second breast conserving treatment: alternative to mastectomy? Results from a prospective trial. Radiother Oncol 2012; 102: 96-101
• 48 Owen JR, Ashton A, Bliss JM. et al. Effect of radiotherapy fraction size on tumour control in patients with early-stage breast cancer after local tumour excision: long-term results of a randomised trial. Lancet Oncol 2006; 7: 467-471
• 49 Haviland JS, Owen JR, Dewar JA. et al. The UK Standardisation of Breast Radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10-year follow-up results of two randomised controlled trials. Lancet Oncol 2013; 14: 1086-1094
• 50 Whelan TJ, Pignol JP, Levine MN. et al. Long-term results of hypofractionated radiation therapy for breast cancer. N Engl J Med 2010; 362: 513-520
• 51 Yarnold J, Ashton A, Bliss J. et al. Fractionation sensitivity and dose response of late adverse effects in the breast after radiotherapy for early breast cancer: long-term results of a randomised trial. Radiother Oncol 2005; 75: 9-17
• 52 START Trialistsʼ Group. Bentzen SM, Agrawal RK, Aird EG. et al. The UK Standardisation of Breast Radiotherapy (START) Trial A of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. Lancet Oncol 2008; 9: 331-341
• 53 START Trialistsʼ Group. Bentzen SM, Agrawal RK, Aird EG. et al. The UK Standardisation of Breast Radiotherapy (START) Trial B of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. Lancet 2008; 371: 1098-1107
• 54 Shaitelman SF, Schlembach PJ, Arzu I. et al. Acute and Short-term Toxic Effects of Conventionally Fractionated vs. Hypofractionated Whole-Breast Irradiation: A Randomized Clinical Trial. JAMA Oncol 2015; 1: 931-941
• 55 Antonini N, Jones H, Horiot JC. et al. Effect of age and radiation dose on local control after breast conserving treatment: EORTC trial 22881-10882. Radiother Oncol 2007; 82: 265-271
• 56 Bartelink H, Maingon P, Poortmans P. et al. Whole-breast irradiation with or without a boost for patients treated with breast-conserving surgery for early breast cancer: 20-year follow-up of a randomised phase 3 trial. Lancet Oncol 2015; 16: 47-56
• 57 Vrieling C, van Werkhoven E, Maingon P. et al. Prognostic Factors for Local Control in Breast Cancer After Long-term Follow-up in the EORTC Boost vs. No Boost Trial: A Randomized Clinical Trial. JAMA Oncol 2017; 3: 42-48
• 58 Romestaing P, Lehingue Y, Carrie C. et al. Role of a 10-Gy boost in the conservative treatment of early breast cancer: results of a randomized clinical trial in Lyon, France. J Clin Oncol 1997; 15: 963-968
• 59 Polgár C, Van Limbergen E, Pötter R. et al. Patient selection for accelerated partial-breast irradiation (APBI) after breast-conserving surgery: recommendations of the Groupe Européen de Curiethérapie-European Society for Therapeutic Radiology and Oncology (GEC-ESTRO) breast cancer working group based on clinical evidence (2009). Radiother Oncol 2010; 94: 264-273
• 60 Polgár C, Fodor J, Major T. et al. Breast-conserving therapy with partial or whole breast irradiation: ten-year results of the Budapest randomized trial. Radiother Oncol 2013; 108: 197-202
• 61 Veronesi U, Orecchia R, Maisonneuve P. et al. Intraoperative radiotherapy versus external radiotherapy for early breast cancer (ELIOT): a randomised controlled equivalence trial. Lancet Oncol 2013; 14: 1269-1277
• 62 Vaidya JS, Wenz F, Bulsara M. et al. Risk-adapted targeted intraoperative radiotherapy versus whole-breast radiotherapy for breast cancer: 5-year results for local control and overall survival from the TARGIT-A randomised trial. Lancet 2014; 383: 603-613
• 63 Strnad V, Ott OJ, Hildebrandt G. et al. 5-year results of accelerated partial breast irradiation using sole interstitial multicatheter brachytherapy versus whole-breast irradiation with boost after breast-conserving surgery for low-risk invasive and in-situ carcinoma of the female breast: a randomised, phase 3, non-inferiority trial. Lancet 2016; 387: 229-238
• 64 Polgár C, Ott OJ, Hildebrandt G. et al. Late side-effects and cosmetic results of accelerated partial breast irradiation with interstitial brachytherapy versus whole-breast irradiation after breast-conserving surgery for low-risk invasive and in-situ carcinoma of the female breast: 5-year results of a randomised, controlled, phase 3 trial. Lancet Oncol 2017; 18: 259-268
• 65 EBCTCG (Early Breast Cancer Trialistsʼ Collaborative Group). McGale P, Taylor C, Correa C. et al. Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: meta-analysis of individual patient data for 8135 women in 22 randomised trials. Lancet 2014; 383: 2127-2135
• 66 Gradishar WJ, Anderson BO, Balassanian R. et al. Invasive breast cancer version 1.2016, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw 2016; 14: 324-354
• 67 Wang H, Kong L, Zhang C. et al. Should all breast cancer patients with four or more positive lymph nodes who underwent modified radical mastectomy be treated with postoperative radiotherapy? A population-based study. Oncotarget 2016; 7: 75492-75502
• 68 Elmore L, Deshpande A, Daly M. et al. Postmastectomy radiation therapy in T3 node-negative breast cancer. J Surg Res 2015; 199: 90-96
• 69 Francis SR, Frandsen J, Kokeny KE. et al. Outcomes and utilization of postmastectomy radiotherapy for T3N0 breast cancers. Breast 2017; 32: 156-161
• 70 Karlsson P, Cole BF, Chua BH. et al. Patterns and risk factors for locoregional failures after mastectomy for breast cancer: an International Breast Cancer Study Group report. Ann Oncol 2012; 23: 2852-2858
• 71 Kyndi M, Overgaard M, Nielsen HM. et al. High local recurrence risk is not associated with large survival reduction after postmastectomy radiotherapy in high-risk breast cancer: a subgroup analysis of DBCG 82 b & c. Radiother Oncol 2009; 90: 74-79
• 72 Nagao T, Kinoshita T, Tamura N. et al. Locoregional recurrence risk factors in breast cancer patients with positive axillary lymph nodes and the impact of postmastectomy radiotherapy. Int J Clin Oncol 2013; 18: 54-61
• 73 Danish Breast Cancer Cooperative Group. Nielsen HM, Overgaard M, Grau C. et al. Study of failure pattern among high-risk breast cancer patients with or without postmastectomy radiotherapy in addition to adjuvant systemic therapy: long-term results from the Danish Breast Cancer Cooperative Group DBCG 82 b and c randomized studies. J Clin Oncol 2006; 24: 2268-2275
• 74 Recht A, Comen EA, Fine RE. et al. Postmastectomy Radiotherapy: An American Society of Clinical Oncology, American Society for Radiation Oncology, and Society of Surgical Oncology Focused Guideline Update. J Clin Oncol 2016; 34: 4431-4442
• 75 Wang H, Zhang C, Kong L. et al. Better survival in PMRT of female breast cancer patients with >5 negative lymph nodes: A population-based study. Medicine (Baltimore) 2017; 96: e5998
• 76 Headon H, Kasem A, Almukbel R. et al. Improvement of survival with postmastectomy radiotherapy in patients with 1–3 positive axillary lymph nodes: A systematic review and meta-analysis of the current literature. Mol Clin Oncol 2016; 5: 429-436
• 77 Valli MC. Controversies in loco-regional treatment: post-mastectomy radiation for pT2-pT3N0 breast cancer arguments in favour. Crit Rev Oncol Hematol 2012; 84 (Suppl. 01) e70-e74
• 78 Overgaard M, Hansen PS, Overgaard J. et al. Postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant chemotherapy. Danish Breast Cancer Cooperative Group 82b Trial. N Engl J Med 1997; 337: 949-955
• 79 Overgaard M, Jensen MB, Overgaard J. et al. Postoperative radiotherapy in high-risk postmenopausal breast-cancer patients given adjuvant tamoxifen: Danish Breast Cancer Cooperative Group DBCG 82c randomised trial. Lancet 1999; 353: 1641-1648
• 80 Rusthoven CG, Rabinovitch RA, Jones BL. et al. The impact of postmastectomy and regional nodal radiation after neoadjuvant chemotherapy for clinically lymph node-positive breast cancer: a National Cancer Database (NCDB) analysis. Ann Oncol 2016; 27: 818-827
• 81 Mamounas EP, Anderson SJ, Dignam JJ. et al. Predictors of locoregional recurrence after neoadjuvant chemotherapy: results from combined analysis of National Surgical Adjuvant Breast and Bowel Project B-18 and B-27. J Clin Oncol 2012; 30: 3960-3966
• 82 Kishan AU, McCloskey SA. Postmastectomy radiation therapy after neoadjuvant chemotherapy: review and interpretation of available data. Ther Adv Med Oncol 2016; 8: 85-97
• 83 Kantor O, Pesce C, Singh P. et al. Post-mastectomy radiation therapy and overall survival after neoadjuvant chemotherapy. J Surg Oncol 2017; 115: 668-676 doi:10.1002/jso.24551
• 84 Poortmans PM, Collette S, Kirkove C. et al. Internal mammary and medial supraclavicular irradiation in breast cancer. N Engl J Med 2015; 373: 317-327
• 85 Thorsen LB, Offersen BV, Danø H. et al. DBCG-IMN: A Population-Based Cohort Study on the Effect of Internal Mammary Node Irradiation in Early Node-Positive Breast Cancer. J Clin Oncol 2016; 34: 314-320
• 86 Whelan TJ, Olivotto IA, Parulekar WR. et al. Regional nodal irradiation in early-stage breast cancer. N Engl J Med 2015; 373: 307-316
• 87 Hennequin C, Bossard N, Servagi-Vernat S. et al. Ten-year survival results of a randomized trial of irradiation of internal mammary nodes after mastectomy. Int J Radiat Oncol Biol Phys 2013; 86: 860-866
• 88 Budach W, Bölke E, Kammers K. et al. Adjuvant radiation therapy of regional lymph nodes in breast cancer – a meta-analysis of randomized trials- an update. Radiat Oncol 2015; 10: 258
• 89 Recht A, Edge SB, Solin LJ. et al. Postmastectomy radiotherapy: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol 2001; 19: 1539-1569
• 90 Yates L, Kirby A, Crichton S. et al. Risk factors for regional nodal relapse in breast cancer patients with one to three positive axillary nodes. Int J Radiat Oncol Biol Phys 2012; 82: 2093-2103
• 91 Caussa L, Kirova YM, Gault N. et al. The acute skin and heart toxicity of a concurrent association of trastuzumab and locoregional breast radiotherapy including internal mammary chain: a single-institution study. Eur J Cancer 2011; 47: 65-73
• 92 Shaffer R, Tyldesley S, Rolles M. et al. Acute cardiotoxicity with concurrent trastuzumab and radiotherapy including internal mammary chain nodes: a retrospective single-institution study. Radiother Oncol 2009; 90: 122-126
• 93 Donker M, van Tienhoven G, Straver ME. et al. Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC10981–22023 AMAROS): a randomised, multicentre, open-label, phase 3 non-inferiority trial. Lancet Oncol 2014; 15: 1303-1310
• 94 Gruber G, Cole BF, Castiglione-Gertsch M. et al. Extracapsular tumor spread and the risk of local, axillary and supraclavicular recurrence in node-positive, premenopausal patients with breast cancer. Ann Oncol 2008; 19: 1393-1401
• 95 Jagsi R, Chadha M, Moni J. et al. Radiation field design in the ACOSOG Z0011 (Alliance) Trial. J Clin Oncol 2014; 32: 3600-3606
• 96 Bartelink H, Rubens RD, van der Schueren E. et al. Hormonal therapy prolongs survival in irradiated locally advanced breast cancer: a European Organization for Research and Treatment of Cancer Randomized Phase III Trial. J Clin Oncol 1997; 15: 207-215
• 97 Scotti V, Desideri I, Meattini I. et al. Management of inflammatory breast cancer: focus on radiotherapy with an evidence-based approach. Cancer Treat Rev 2013; 39: 119-124
• 98 Bellon JR, Come SE, Gelman RS. et al. Sequencing of chemotherapy and radiation therapy in early-stage breast cancer: updated results of a prospective randomized trial. J Clin Oncol 2005; 23: 1934-1940
• 99 Hickey BE, Francis D, Lehman MH. Sequencing of chemotherapy and radiation therapy for early breast cancer. Cochrane Database Syst Rev 2006; (04) CD005212
• 100 Hickey BE, Francis DP, Lehman M. Sequencing of chemotherapy and radiotherapy for early breast cancer. Cochrane Database Syst Rev 2013; (04) CD005212
• 101 Pinnarò P, Rambone R, Giordano C. et al. Long-term results of a randomized trial on the sequencing of radiotherapy and chemotherapy in breast cancer. Am J Clin Oncol 2011; 34: 238-244
• 102 Chen Z, King W, Pearcey R. et al. The relationship between waiting time for radiotherapy and clinical outcomes: a systematic review of the literature. Radiother Oncol 2008; 87: 3-16
• 103 Huang J, Barbera L, Brouwers M. et al. Does delay in starting treatment affect the outcomes of radiotherapy? A systematic review. J Clin Oncol 2003; 21: 555-563
• 104 Halyard MY, Pisansky TM, Dueck AC. et al. Radiotherapy and adjuvant trastuzumab in operable breast cancer: tolerability and adverse event data from the NCCTG Phase III Trial N9831. J Clin Oncol 2009; 27: 2638-2644
• 105 Li YF, Chang L, Li WH. et al. Radiotherapy concurrent versus sequential with endocrine therapy in breast cancer: A meta-analysis. Breast 2016; 27: 93-98
• 106 Goldhirsch A, Wood WC, Coates AS. et al. Strategies for subtypes – dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol 2011; 22: 1736-1747
• 107 Polychemotherapy for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialistsʼ Collaborative Group. Lancet 1998; 352: 930-942
• 108 Early Breast Cancer Trialistsʼ Collaborative Group (EBCTCG). Davies C, Godwin J, Gray R. et al. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet 2011; 378: 771-784
• 109 Fisher B, Dignam J, Wolmark N. et al. Tamoxifen and chemotherapy for lymph node-negative, estrogen receptor-positive breast cancer. J Natl Cancer Inst 1997; 89: 1673-1682
• 110 The International Breast Cancer Study Group. Thürlimann B, Price KN, Castiglione M. et al. Randomized controlled trial of ovarian function suppression plus tamoxifen versus the same endocrine therapy plus chemotherapy: Is chemotherapy necessary for premenopausal women with node-positive, endocrine-responsive breast cancer? First results of International Breast Cancer Study Group Trial 11-93. The Breast 2001; 10: 130-138
• 111 Burstein HJ, Temin S, Anderson H. et al. Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: American Society of Clinical Oncology clinical practice guideline focused update. J Clin Oncol 2014; 32: 2255-2269
• 112 Davies C, Pan H, Godwin J. et al. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet 2013; 381: 805-816
• 113 Gray RG, Rea D, Handley K. aTTom: Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years in 6,953 women with early breast cancer. J Clin Oncol 2013; 31 (Suppl. 18) 5 doi:10.1200/jco.2013.31.18_suppl.5
• 114 Rea DW, Gray RG, Bowden SJ. Overall and subgroup findings of the aTTom trial: A randomised comparison of continuing adjuvant tamoxifen to 10 years compared to stopping after 5 years in 6953 women with ER positive or ER untested early breast cancer. Eur J Cancer 2013; 49: S402
• 115 Eisen A, Fletcher GG, Gandhi S. et al. Optimal Systemic Therapy for Early Female Breast Cancer. Toronto (ON): Cancer Care Ontario; 2014 Sep 30. Program in Evidence-Based Care Evidence-Based Series No.: 1–21.
• 116 Ferguson T, Wilcken N, Vagg R. et al. Taxanes for adjuvant treatment of early breast cancer. Cochrane Database Syst Rev 2007; (04) CD004421
• 117 Sparano JA, Zhao F, Martino S. et al. Long-Term Follow-Up of the E1199 Phase III Trial Evaluating the Role of Taxane and Schedule in Operable Breast Cancer. J Clin Oncol 2015; 33: 2353-2360
• 118 Early Breast Cancer Trialistsʼ Collaborative Group (EBCTCG). Peto R, Davies C, Godwin J. et al. Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials. Lancet 2012; 379: 432-444
• 119 Early Breast Cancer Trialists' Collaborative Group. EBM Reviews. Multi-agent chemotherapy for early breast cancer. Cochrane Database Syst Rev 2003; (01) CD000487
• 120 Budman DR, Berry DA, Cirrincione CT. et al. Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer. The Cancer and Leukemia Group B. J Natl Cancer Inst 1998; 90: 1205-1211
• 121 Fisher B, Anderson S, Wickerham DL. et al. Increased intensification and total dose of cyclophosphamide in a doxorubicin-cyclophosphamide regimen for the treatment of primary breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-22. J Clin Oncol 1997; 15: 1858-1869
• 122 French Adjuvant Study Group. Benefit of a high-dose epirubicin regimen in adjuvant chemotherapy for node-positive breast cancer patients with poor prognostic factors: 5-year follow-up results of French Adjuvant Study Group 05 randomized trial. J Clin Oncol 2001; 19: 602-611
• 123 Fumoleau P, Kerbrat P, Romestaing P. et al. Randomized trial comparing six versus three cycles of epirubicin-based adjuvant chemotherapy in premenopausal, node-positive breast cancer patients: 10-year follow-up results of the French Adjuvant Study Group 01 trial. J Clin Oncol 2003; 21: 298-305
• 124 Swain SM, Jeong JH, Geyer jr. CE. et al. Longer therapy, iatrogenic amenorrhea, and survival in early breast cancer. N Engl J Med 2010; 362: 2053-2065
• 125 Bonadonna G, Zambetti M, Valagussa P. Sequential or alternating doxorubicin and CMF regimens in breast cancer with more than three positive nodes. Ten-year results. JAMA 1995; 273: 542-547
• 126 Citron ML, Berry DA, Cirrincione C. et al. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol 2003; 21: 1431-1439
• 127 Eiermann W, Pienkowski T, Crown J. et al. Phase III study of doxorubicin/cyclophosphamide with concomitant versus sequential docetaxel as adjuvant treatment in patients with human epidermal growth factor receptor 2-normal, node-positive breast cancer: BCIRG-005 trial. J Clin Oncol 2011; 29: 3877-3884
• 128 Francis P, Crown J, Di Leo A. et al. Adjuvant chemotherapy with sequential or concurrent anthracycline and docetaxel: Breast International Group 02-98 randomized trial. J Natl Cancer Inst 2008; 100: 121-133
• 129 Moebus V, Jackisch C, Lueck HJ. et al. Intense dose-dense sequential chemotherapy with epirubicin, paclitaxel, and cyclophosphamide compared with conventionally scheduled chemotherapy in high-risk primary breast cancer: mature results of an AGO phase III study. J Clin Oncol 2010; 28: 2874-2880
• 130 Del Mastro L, De Placido S, Bruzzi P. et al. Fluorouracil and dose-dense chemotherapy in adjuvant treatment of patients with early-stage breast cancer: an open-label, 2 × 2 factorial, randomised phase 3 trial. Lancet 2015; 385: 1863-1872
• 131 Bria E, Nistico C, Cuppone F. et al. Benefit of taxanes as adjuvant chemotherapy for early breast cancer: pooled analysis of 15,500 patients. Cancer 2006; 106: 2337-2344
• 132 Clavarezza M, Del Mastro L, Venturini M. Taxane-containing chemotherapy in the treatment of early breast cancer patients. Ann Oncol 2006; 17 (Suppl. 07) vii22-vii26
• 133 Estévez LG, Muñoz M, Alvarez I. et al. Evidence-based use of taxanes in the adjuvant setting of breast cancer. A review of randomized phase III trials. Cancer Treat Rev 2007; 33: 474-483
• 134 Henderson IC, Berry DA, Demetri GD. et al. Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol 2003; 21: 976-983
• 135 Mamounas EP, Bryant J, Lembersky B. et al. Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: results from NSABP B-28. J Clin Oncol 2005; 23: 3686-3696
• 136 Roché H, Fumoleau P, Spielmann M. et al. Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients: the FNCLCC PACS01 Trial. J Clin Oncol 2006; 24: 5664-5671
• 137 Blum JL, Flynn PJ, Yothers G. et al. Anthracyclines in Early Breast Cancer: The ABC Trials-USOR 06-090, NSABP B-46-I/USOR 07132, and NSABP B-49 (NRG Oncology). J Clin Oncol 2017; 35: 2647-2655
• 138 Ejlertsen B, Tuxen MK, Jakobsen EH. et al. Adjuvant Cyclophosphamide and Docetaxel With or Without Epirubicin for Early TOP2A-Normal Breast Cancer: DBCG 07-READ, an Open-Label, Phase III, Randomized Trial. J Clin Oncol 2017; 35: 2639-2646 doi:10.1200/JCO.2017.72.3494
• 139 Harbeck N, Gluz O, Clemens MR. et al. Prospective WSG phase III PlanB trial: Final analysis of adjuvant 4xEC→4x doc vs. 6x docetaxel/cyclophosphamide in patients with high clinical risk and intermediate-to-high genomic risk HER2-negative, early breast cancer. J Clin Oncol 2017; 35 (Suppl. 15) 504
• 140 von Minckwitz G, Untch M, Nüesch E. et al. Impact of treatment characteristics on response of different breast cancer phenotypes: pooled analysis of the German neo-adjuvant chemotherapy trials. Breast Cancer Res Treat 2011; 125: 145-156
• 141 Cortazar P, Zhang L, Untch M. et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet 2014; 384: 164-172
• 142 Kaufmann M, Hortobagyi GN, Goldhirsch A. et al. Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: an update. J Clin Oncol 2006; 24: 1940-1949
• 143 Bear HD, Anderson S, Smith RE. et al. Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol 2006; 24: 2019-2027
• 144 von Minckwitz G, Blohmer JU, Raab G. et al. In vivo chemosensitivity-adapted preoperative chemotherapy in patients with early-stage breast cancer: the GEPARTRIO pilot study. Ann Oncol 2005; 16: 56-63
• 145 Petrelli F, Barni S. Meta-analysis of concomitant compared to sequential adjuvant trastuzumab in breast cancer: the sooner the better. Med Oncol 2012; 29: 503-510
• 146 Pfeilschifter J, Diel IJ. Osteoporosis due to cancer treatment: pathogenesis and management. J Clin Oncol 2000; 18: 1570-1593
• 147 Gnant M, Mlineritsch B, Schippinger W. et al. Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N Engl J Med 2009; 360: 679-691
• 148 Gnant M, Mlineritsch B, Stoeger H. et al. Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial. Lancet Oncol 2011; 12: 631-641
• 149 Hadji P, Kauka A, Ziller M. et al. Effects of zoledronic acid on bone mineral density in premenopausal women receiving neoadjuvant or adjuvant therapies for HR+ breast cancer: the ProBONE II study. Osteoporos Int 2014; 25: 1369-1378
• 150 Gnant M, Pfeiler G, Dubsky PC. et al. Adjuvant denosumab in breast cancer (ABCSG-18): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet 2015; 386: 433-443
• 151 Kalder M, Hans D, Kyvernitakis I. et al. Effects of Exemestane and Tamoxifen treatment on bone texture analysis assessed by TBS in comparison with bone mineral density assessed by DXA in women with breast cancer. J Clin Densitom 2014; 17: 66-71
• 152 Hadji P, Asmar L, van Nes JG. et al. The effect of exemestane and tamoxifen on bone health within the Tamoxifen Exemestane Adjuvant Multinational (TEAM) trial: a meta-analysis of the US, German, Netherlands, and Belgium sub-studies. J Cancer Res Clin Oncol 2011; 137: 1015-1025
• 153 Rabaglio M, Sun Z, Price KN. et al. Bone fractures among postmenopausal patients with endocrine-responsive early breast cancer treated with 5 years of letrozole or tamoxifen in the BIG 1-98 trial. Ann Oncol 2009; 20: 1489-1498
• 154 Greep NC, Giuliano AE, Hansen NM. et al. The effects of adjuvant chemotherapy on bone density in postmenopausal women with early breast cancer. Am J Med 2003; 114: 653-659
• 155 Hadji P, Ziller M, Maskow C. et al. The influence of chemotherapy on bone mineral density, quantitative ultrasonometry and bone turnover in pre-menopausal women with breast cancer. Eur J Cancer 2009; 45: 3205-3212
• 156 Kanis JA, Oden A, Johnell O. et al. The use of clinical risk factors enhances the performance of BMD in the prediction of hip and osteoporotic fractures in men and women. Osteoporos Int 2007; 18: 1033-1046
• 157 Frost SA, Nguyen ND, Center JR. et al. Timing of repeat BMD measurements: development of an absolute risk-based prognostic model. J Bone Miner Res 2009; 24: 1800-1807
• 158 Coleman R, Cameron D, Dodwell D. et al. Adjuvant zoledronic acid in patients with early breast cancer: final efficacy analysis of the AZURE (BIG 01/04) randomised open-label phase 3 trial. Lancet Oncol 2014; 15: 997-1006
• 159 Col NF, Hirota LK, Orr RK. et al. Hormone replacement therapy after breast cancer: a systematic review and quantitative assessment of risk. J Clin Oncol 2001; 19: 2357-2363
• 160 Pantel K, Alix-Panabieres C, Riethdorf S. Cancer micrometastases. Nat Rev Clin Oncol 2009; 6: 339-351
• 161 Wilson C, Holen I, Coleman RE. Seed, soil and secreted hormones: potential interactions of breast cancer cells with their endocrine/paracrine microenvironment and implications for treatment with bisphosphonates. Cancer Treat Rev 2012; 38: 877-889
• 162 Domschke C, Diel IJ, Englert S. et al. Prognostic value of disseminated tumor cells in the bone marrow of patients with operable primary breast cancer: a long-term follow-up study. Ann Surg Oncol 2013; 20: 1865-1871
• 163 Banys M, Solomayer EF, Gebauer G. et al. Influence of zoledronic acid on disseminated tumor cells in bone marrow and survival: results of a prospective clinical trial. BMC Cancer 2013; 13: 480
• 164 Ben-Aharon I, Vidal L, Rizel S. et al. Bisphosphonates in the adjuvant setting of breast cancer therapy – effect on survival: a systematic review and meta-analysis. PLoS One 2013; 8: e70044
• 165 Early Breast Cancer Trialistsʼ Collaborative Group (EBCTCG). Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials. Lancet 2015; 386: 1353-1361
• 166 Coleman R, Body JJ, Aapro M. et al. Bone health in cancer patients: ESMO Clinical Practice Guidelines. Ann Oncol 2014; 25 (Suppl. 03) iii124-iii137
• 167 Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF). http://
• 168 Grunfeld E, Dhesy-Thind S, Levine M. Clinical practice guidelines for the care and treatment of breast cancer: follow-up after treatment for breast cancer (summary of the 2005 update). CMAJ 2005; 172: 1319-1320
• 169 Hauner D, Janni W, Rack B. et al. The effect of overweight and nutrition on prognosis in breast cancer. Dtsch Arztebl Int 2011; 108: 795-801
• 170 Voskuil DW, van Nes JG, Junggeburt JM. et al. Maintenance of physical activity and body weight in relation to subsequent quality of life in postmenopausal breast cancer patients. Ann Oncol 2010; 21: 2094-2101
• 171 Rock CL, Doyle C, Demark-Wahnefried W. et al. Nutrition and physical activity guidelines for cancer survivors. CA Cancer J Clin 2012; 62: 243-274
• 172 Cheema BS, Kilbreath SL, Fahey PP. et al. Safety and efficacy of progressive resistance training in breast cancer: a systematic review and meta-analysis. Breast Cancer Res Treat 2014; 148: 249-268
• 173 Courneya KS, McKenzie DC, Mackey JR. et al. Subgroup effects in a randomised trial of different types and doses of exercise during breast cancer chemotherapy. Br J Cancer 2014; 111: 1718-1725
• 174 Irwin ML, Cartmel B, Gross CP. et al. Randomized exercise trial of aromatase inhibitor-induced arthralgia in breast cancer survivors. J Clin Oncol 2015; 33: 1104-1111
• 175 Steindorf K, Schmidt ME, Klassen O. et al. Randomized, controlled trial of resistance training in breast cancer patients receiving adjuvant radiotherapy: results on cancer-related fatigue and quality of life. Ann Oncol 2014; 25: 2237-2243
• 176 Furmaniak AC, Menig M, Markes MH. Exercise for women receiving adjuvant therapy for breast cancer. Cochrane Database Syst Rev 2016; (09) CD005001
• 177 Meneses-Echavez JF, Gonzalez-Jimenez E, Ramirez-Velez R. Effects of supervised exercise on cancer-related fatigue in breast cancer survivors: a systematic review and meta-analysis. BMC Cancer 2015; 15: 77
• 178 Bower JE, Bak K, Berger A. et al. Screening, assessment, and management of fatigue in adult survivors of cancer: an American Society of Clinical oncology clinical practice guideline adaptation. J Clin Oncol 2014; 32: 1840-1850
• 179 Carayol M, Bernard P, Boiché J. et al. Psychological effect of exercise in women with breast cancer receiving adjuvant therapy: what is the optimal dose needed?. Ann Oncol 2013; 24: 291-300
• 180 Mishra SI, Scherer RW, Geigle PM. et al. Exercise interventions on health-related quality of life for cancer survivors. Cochrane Database Syst Rev 2012; (08) CD007566
• 181 Streckmann F, Kneis S, Leifert JA. et al. Exercise program improves therapy-related side-effects and quality of life in lymphoma patients undergoing therapy. Ann Oncol 2014; 25: 493-499
• 182 Keilani M, Hasenoehrl T, Neubauer M. et al. Resistance exercise and secondary lymphedema in breast cancer survivors – a systematic review. Support Care Cancer 2016; 24: 1907-1916
• 183 Nelson NL. Breast Cancer-Related Lymphedema and Resistance Exercise: A Systematic Review. J Strength Cond Res 2016; 30: 2656-2665
• 184 Bok SK, Jeon Y, Hwang PS. Ultrasonographic Evaluation of the Effects of Progressive Resistive Exercise in Breast Cancer-Related Lymphedema. Lymphat Res Biol 2016; 14: 18-24
• 185 Letellier ME, Towers A, Shimony A. et al. Breast cancer-related lymphedema: a randomized controlled pilot and feasibility study. Am J Phys Med Rehabil 2014; 93: 751-759 quiz 760–761
• 186 Cormie P, Galvão DA, Spry N. et al. Neither heavy nor light load resistance exercise acutely exacerbates lymphedema in breast cancer survivor. Integr Cancer Ther 2013; 12: 423-432
• 187 Cormie P, Pumpa K, Galvão DA. et al. Is it safe and efficacious for women with lymphedema secondary to breast cancer to lift heavy weights during exercise: a randomised controlled trial. J Cancer Surviv 2013; 7: 413-424
• 188 Runowicz CD, Leach CR, Henry NL. et al. American Cancer society/American society of clinical oncology breast Cancer survivorship care guideline. CA Cancer J Clin 2016; 66: 43-73
• 189 Nechuta S, Chen WY, Cai H. et al. A pooled analysis of post-diagnosis lifestyle factors in association with late estrogen-receptor-positive breast cancer prognosis. Int J Cancer 2016; 138: 2088-2097
• 190 Azim jr. HA, Kroman N, Paesmans M. et al. Prognostic impact of pregnancy after breast cancer according to estrogen receptor status: a multicenter retrospective study. J Clin Oncol 2013; 31: 73-79
• 191 Azim jr. HA, Santoro L, Pavlidis N. et al. Safety of pregnancy following breast cancer diagnosis: a meta-analysis of 14 studies. Eur J Cancer 2011; 47: 74-83
• 192 Goldrat O, Kroman N, Peccatori FA. et al. Pregnancy following breast cancer using assisted reproduction and its effect on long-term outcome. Eur J Cancer 2015; 51: 1490-1496
• 193 Lambertini M, Del Mastro L, Pescio MC. et al. Cancer and fertility preservation: international recommendations from an expert meeting. BMC Med 2016; 14: 1
• 194 Gennari A, Costa M, Puntoni M. et al. Breast cancer incidence after hormonal treatments for infertility: systematic review and meta-analysis of population-based studies. Breast Cancer Res Treat 2015; 150: 405-413
• 195 Luke B, Brown MB, Missmer SA. et al. Assisted reproductive technology use and outcomes among women with a history of cancer. Hum Reprod 2016; 31: 183-189
• 196 Loibl S, Han SN, von Minckwitz G. et al. Treatment of breast cancer during pregnancy: an observational study. Lancet Oncol 2012; 13: 887-896
• 197 Loibl S, Schmidt A, Gentilini O. et al. Breast Cancer Diagnosed During Pregnancy: Adapting Recent Advances in Breast Cancer Care for Pregnant Patients. JAMA Oncol 2015; 1: 1145-1153
• 198 National Toxicology Program. NTP Monograph: Developmental Effects and Pregnancy Outcomes Associated With Cancer Chemotherapy Use During Pregnancy. NTP Monogr 2013; (02) i-214
• 199 Zagouri F, Sergentanis TN, Chrysikos D. et al. Trastuzumab administration during pregnancy: a systematic review and meta-analysis. Breast Cancer Res Treat 2013; 137: 349-357
• 200 Del Mastro L, Rossi G, Lambertini M. et al. New insights on the role of luteinizing hormone releasing hormone agonists in premenopausal early breast cancer patients. Cancer Treat Rev 2016; 42: 18-23
• 201 Vitek WS, Shayne M, Hoeger K. et al. Gonadotropin-releasing hormone agonists for the preservation of ovarian function among women with breast cancer who did not use tamoxifen after chemotherapy: a systematic review and meta-analysis. Fertil Steril 2014; 102: 808-815.e1
• 202 Moore HC, Unger JM, Phillips KA. et al. Goserelin for ovarian protection during breast-cancer adjuvant chemotherapy. N Engl J Med 2015; 372: 923-932
• 203 Del Mastro L, Boni L, Michelotti A. et al. Effect of the gonadotropin-releasing hormone analogue triptorelin on the occurrence of chemotherapy-induced early menopause in premenopausal women with breast cancer: a randomized trial. JAMA 2011; 306: 269-276
• 204 Lambertini M, Boni L, Michelotti A. et al. Ovarian Suppression With Triptorelin During Adjuvant Breast Cancer Chemotherapy and Long-term Ovarian Function, Pregnancies, and Disease-Free Survival: A Randomized Clinical Trial. JAMA 2015; 314: 2632-2640
• 205 Gerber B, von Minckwitz G, Stehle H. et al. Effect of luteinizing hormone-releasing hormone agonist on ovarian function after modern adjuvant breast cancer chemotherapy: the GBG 37 ZORO study. J Clin Oncol 2011; 29: 2334-2341
• 206 Munster PN, Moore AP, Ismail-Khan R. et al. Randomized trial using gonadotropin-releasing hormone agonist triptorelin for the preservation of ovarian function during (neo)adjuvant chemotherapy for breast cancer. J Clin Oncol 2012; 30: 533-538
• 207 Kalsi T, Babic-Illman G, Ross PJ. et al. The impact of comprehensive geriatric assessment interventions on tolerance to chemotherapy in older people. Br J Cancer 2015; 112: 1435-1444
• 208 Hall DE, Arya S, Schmid KK. et al. Association of a Frailty Screening Initiative With Postoperative Survival at 30, 180, and 365 Days. JAMA Surg 2017; 152: 233-240
• 209 Le Saux O, Ripamonti B, Bruyas A. et al. Optimal management of breast cancer in the elderly patient: current perspectives. Clin Interv Aging 2015; 10: 157-174
• 210 Decoster L, Van Puyvelde K, Mohile S. et al. Screening tools for multidimensional health problems warranting a geriatric assessment in older cancer patients: an update on SIOG recommendations†. Ann Oncol 2015; 26: 288-300
• 211 Clough-Gorr KM, Stuck AE, Thwin SS. et al. Older breast cancer survivors: geriatric assessment domains are associated with poor tolerance of treatment adverse effects and predict mortality over 7 years of follow-up. J Clin Oncol 2010; 28: 380-386
• 212 Mislang AR, Biganzoli L. Adjuvant Systemic Therapy in Older Breast Cancer Women: Can We Optimize the Level of Care?. Cancers (Basel) 2015; 7: 1191-1214
• 213 Biganzoli L, Wildiers H, Oakman C. et al. Management of elderly patients with breast cancer: updated recommendations of the International Society of Geriatric Oncology (SIOG) and European Society of Breast Cancer Specialists (EUSOMA). Lancet Oncol 2012; 13: e148-e160
• 214 Thavarajah N, Menjak I, Trudeau M. et al. Towards an optimal multidisciplinary approach to breast cancer treatment for older women. Can Oncol Nurs J 2015; 25: 384-408
• 215 Morgan J, Wyld L, Collins KA. et al. Surgery versus primary endocrine therapy for operable primary breast cancer in elderly women (70 years plus). Cochrane Database Syst Rev 2014; (05) CD004272 DOI: 10.1002/14651858.CD004272.pub3.
• 216 Christiansen P, Bjerre K, Ejlertsen B. et al. Mortality rates among early-stage hormone receptor-positive breast cancer patients: a population-based cohort study in Denmark. J Natl Cancer Inst 2011; 103: 1363-1372
• 217 Lange M, Heutte N, Rigal O. et al. Decline in Cognitive Function in Older Adults With Early-Stage Breast Cancer After Adjuvant Treatment. Oncologist 2016; 21: 1337-1348 doi:10.1634/theoncologist.2016-0014
• 218 Ono M, Ogilvie JM, Wilson JS. et al. A meta-analysis of cognitive impairment and decline associated with adjuvant chemotherapy in women with breast cancer. Front Oncol 2015; 5: 59
• 219 Jones S, Holmes FA, OʼShaughnessy J. et al. Docetaxel With Cyclophosphamide Is Associated With an Overall Survival Benefit Compared With Doxorubicin and Cyclophosphamide: 7-Year Follow-Up of US Oncology Research Trial 9735. J Clin Oncol 2009; 27: 1177-1183
• 220 Perrone F, Nuzzo F, Di Rella F. et al. Weekly docetaxel versus CMF as adjuvant chemotherapy for older women with early breast cancer: final results of the randomized phase III ELDA trial. Ann Oncol 2015; 26: 675-682
• 221 Biganzoli L, Aapro M, Loibl S. et al. Taxanes in the treatment of breast cancer: Have we better defined their role in older patients? A position paper from a SIOG Task Force. Cancer Treat Rev 2016; 43: 19-26
• 222 Muss HB, Berry DA, Cirrincione CT. et al. Adjuvant chemotherapy in older women with early-stage breast cancer. N Engl J Med 2009; 360: 2055-2065
• 223 Freyer G, Campone M, Peron J. et al. Adjuvant docetaxel/cyclophosphamide in breast cancer patients over the age of 70: results of an observational study. Crit Rev Oncol Hematol 2011; 80: 466-473
• 224 Loibl S, von Minckwitz G, Harbeck N. et al. Clinical feasibility of (neo)adjuvant taxane-based chemotherapy in older patients: analysis of > 4,500 patients from four German randomized breast cancer trials. Breast Cancer Res 2008; 10: R77
• 225 Swain SM, Whaley FS, Ewer MS. Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials. Cancer 2003; 97: 2869-2879
• 226 Freedman RA, Seisler DK, Foster JC. et al. Risk of acute myeloid leukemia and myelodysplastic syndrome among older women receiving anthracycline-based adjuvant chemotherapy for breast cancer on Modern Cooperative Group Trials (Alliance A151511). Breast Cancer Res Treat 2017; 161: 363-373
• 227 Pinder MC, Duan Z, Goodwin JS. et al. Congestive heart failure in older women treated with adjuvant anthracycline chemotherapy for breast cancer. J Clin Oncol 2007; 25: 3808-3815
• 228 Dall P, Lenzen G, Göhler T. et al. Trastuzumab in the treatment of elderly patients with early breast cancer: Results from an observational study in Germany. J Geriatr Oncol 2015; 6: 462-469
• 229 Brollo J, Curigliano G, Disalvatore D. et al. Adjuvant trastuzumab in elderly with HER-2 positive breast cancer: a systematic review of randomized controlled trials. Cancer Treat Rev 2013; 39: 44-50
• 230 Jones SE, Savin MA, Holmes FA. et al. Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer. J Clin Oncol 2006; 24: 5381-5387
• 231 Dang C, Guo H, Najita J. et al. Cardiac Outcomes of Patients Receiving Adjuvant Weekly Paclitaxel and Trastuzumab for Node-Negative, ERBB2-Positive Breast Cancer. JAMA Oncol 2016; 2: 29-36
• 232 Tolaney SM, Barry WT, Dang CT. et al. Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer. N Engl J Med 2015; 372: 134-141
• 233 Castro E, Goh C, Olmos D. et al. Germline BRCA mutations are associated with higher risk of nodal involvement, distant metastasis, and poor survival outcomes in prostate cancer. J Clin Oncol 2013; 31: 1748-1757
• 234 Bundesinstitut für Arzneimittel und Medizinprodukte (BfArM, Bonn), Paul-Ehrlich-Institut (PEI, Langen). BfArM Bulletin zur Arzneimittelsicherheit. 2010. Online: https://www.bfarm.de/DE/Arzneimittel/Pharmakovigilanz/Bulletin/_node.html
• 235 Deutsch M. Repeat high-dose external beam irradiation for in-breast tumor recurrence after previous lumpectomy and whole breast irradiation. Int J Radiat Oncol Biol Phys 2002; 53: 687-691
• 236 Haffty BG, Reiss M, Beinfield M. et al. Ipsilateral breast tumor recurrence as a predictor of distant disease: implications for systemic therapy at the time of local relapse. J Clin Oncol 1996; 14: 52-57
• 237 Kurtz JM, Jacquemier J, Amalric R. et al. Is breast conservation after local recurrence feasible?. Eur J Cancer 1991; 27: 240-244
• 238 Whelan T, Clark R, Roberts R. et al. Ipsilateral breast tumor recurrence postlumpectomy is predictive of subsequent mortality: results from a randomized trial. Investigators of the Ontario Clinical Oncology Group. Int J Radiat Oncol Biol Phys 1994; 30: 11-16
• 239 Fossati R, Confalonieri C, Torri V. et al. Cytotoxic and hormonal treatment for metastatic breast cancer: a systematic review of published randomized trials involving 31,510 women. J Clin Oncol 1998; 16: 3439-3460
• 240 Stockler M, Wilcken N, Ghersi D, Simes RJ. The management of advanced breast cancer: systemic reviews of randomised controlled trials regarding the use of cytotoxic chemotherapy and endocrine therapy. Woolloomooloo: NHMRC National Breast Cancer Centre; 1997
• 241 Stockler M, Wilcken NR, Ghersi D. et al. Systematic reviews of chemotherapy and endocrine therapy in metastatic breast cancer. Cancer Treat Rev 2000; 26: 151-168
• 242 Rugo HS, Rumble RB, Macrae E. et al. Endocrine Therapy for Hormone Receptor-Positive Metastatic Breast Cancer: American Society of Clinical Oncology Guideline. J Clin Oncol 2016; 34: 3069-3103
• 243 Partridge AH, Rumble RB, Carey LA. et al. Chemotherapy and targeted therapy for women with human epidermal growth factor receptor 2-negative (or unknown) advanced breast cancer: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol 2014; 32: 3307-3329
• 244 Sledge jr. GW, Hu P, Falkson G. et al. Comparison of chemotherapy with chemohormonal therapy as first-line therapy for metastatic, hormone-sensitive breast cancer: An Eastern Cooperative Oncology Group study. J Clin Oncol 2000; 18: 262-266
• 245 Klijn JG, Blamey RW, Boccardo F. et al. Combined tamoxifen and luteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist alone in premenopausal advanced breast cancer: a meta-analysis of four randomized trials. J Clin Oncol 2001; 19: 343-353
• 246 National Breast and Ovarian Cancer Centre. Recommendations for follow-up of women with early breast cancer. SurryHills, NSW: National Breast and Ovarian Cancer Centre; 2010. Online: https://guidelines.canceraustralia.gov.au/guidelines/early_breast_cancer/
• 247 Taylor CW, Green S, Dalton WS. et al. Multicenter randomized clinical trial of goserelin versus surgical ovariectomy in premenopausal patients with receptor-positive metastatic breast cancer: an intergroup study. J Clin Oncol 1998; 16: 994-999
• 248 Loibl S, Turner NC, Ro J. et al. Palbociclib (PAL) in combination with fulvestrant (F) in pre-/peri-menopausal (PreM) women with metastatic breast cancer (MBC) and prior progression on endocrine therapy – results from Paloma-3. J Clin Oncol 2016; 34 (Suppl.) Abstr.. 524
• 249 Ellis M, Hayes D, Lippman M. Treatment of metastatic breast cancer. Cancer 2000; 2000: 749-797
• 250 Hayes DF, Henderson IC, Shapiro CL. Treatment of metastatic breast cancer: present and future prospects. Semin Oncol 1995; 22 (2 Suppl. 5): 5-19 discussion 19–21
• 251 Mouridsen H, Gershanovich M, Sun Y. et al. Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group. J Clin Oncol 2001; 19: 2596-2606
• 252 Mouridsen H, Sun Y, Gershanovich M. et al. First-line therapy with letrozole (femara^®) for advanced breast cancer prolongs time to worsening of Karnofsky Performance Status compared with tamoxifen. Breast Cancer Res Treat 2001; 69: 185 doi:10.1023/A:1017475415273
• 253 Dear RF, McGeechan K, Jenkins MC. et al. Combination versus sequential single agent chemotherapy for metastatic breast cancer. Cochrane Database Syst Rev 2013; (12) CD008792
• 254 Sledge GW, Neuberg D, Bernardo P. et al. Phase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: an intergroup trial (E1193). J Clin Oncol 2003; 21: 588-592
• 255 Miller K, Wang M, Gralow J. et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 2007; 357: 2666-2676
• 256 Gray R, Bhattacharya S, Bowden C. et al. Independent review of E2100: a phase III trial of bevacizumab plus paclitaxel versus paclitaxel in women with metastatic breast cancer. J Clin Oncol 2009; 27: 4966-4972
• 257 Robert NJ, Diéras V, Glaspy J. et al. RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2–negative, locally recurrent or metastatic breast cancer. J Clin Oncol 2011; 29: 1252-1260
• 258 Welt A, Marschner N, Lerchenmueller C. et al. Capecitabine and bevacizumab with or without vinorelbine in first-line treatment of HER2/neu-negative metastatic or locally advanced breast cancer: final efficacy and safety data of the randomised, open-label superiority phase 3 CARIN trial. Breast Cancer Res Treat 2016; 156: 97-107
• 259 Lang I, Brodowicz T, Ryvo L. et al. Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer: interim efficacy results of the randomised, open-label, non-inferiority, phase 3 TURANDOT trial. Lancet Oncol 2013; 14: 125-133
• 260 Zielinski C, Láng I, Inbar M. et al. Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer (TURANDOT): primary endpoint results of a randomised, open-label, non-inferiority, phase 3 trial. Lancet Oncol 2016; 17: 1230-1239
• 261 Carrick S, Parker S, Wilcken N. et al. Single agent versus combination chemotherapy for metastatic breast cancer. Cochrane Database Syst Rev 2005; (02) CD003372
• 262 Giordano SH, Temin S, Kirshner JJ. et al. Systemic therapy for patients with advanced human epidermal growth factor receptor 2-positive breast cancer: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol 2014; 32: 2078-2099
• 263 Balduzzi S, Mantarro S, Guarneri V. et al. Trastuzumab-containing regimens for metastatic breast cancer. Cochrane Database Syst Rev 2014; (06) CD006242
• 264 Kalkanis SN, Kondziolka D, Gaspar LE. et al. The role of surgical resection in the management of newly diagnosed brain metastases: a systematic review and evidence-based clinical practice guideline. J Neurooncol 2010; 96: 33-43
• 265 Patchell RA, Tibbs PA, Walsh JW. et al. A randomized trial of surgery in the treatment of single metastases to the brain. N Engl J Med 1990; 322: 494-500
• 266 Vecht CJ, Haaxma-Reiche H, Noordijk EM. et al. Treatment of single brain metastasis: radiotherapy alone or combined with neurosurgery?. Ann Neurol 1993; 33: 583-590
• 267 Patchell RA, Tibbs PA, Regine WF. et al. Postoperative radiotherapy in the treatment of single metastases to the brain: a randomized trial. JAMA 1998; 280: 1485-1489
• 268 Kondziolka D, Patel A, Lunsford LD. et al. Stereotactic radiosurgery plus whole brain radiotherapy versus radiotherapy alone for patients with multiple brain metastases. Int J Radiat Oncol Biol Phys 1999; 45: 427-434
• 269 Andrews DW, Scott CB, Sperduto PW. et al. Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial. Lancet 2004; 363: 1665-1672
• 270 Aoyama H, Shirato H, Tago M. et al. Stereotactic radiosurgery plus whole-brain radiation therapy vs. stereotactic radiosurgery alone for treatment of brain metastases: a randomized controlled trial. JAMA 2006; 295: 2483-2491
• 271 Chang EL, Wefel JS, Hess KR. et al. Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation: a randomised controlled trial. Lancet Oncol 2009; 10: 1037-1044
• 272 Kocher M, Soffietti R, Abacioglu U. et al. Adjuvant whole-brain radiotherapy versus observation after radiosurgery or surgical resection of one to three cerebral metastases: results of the EORTC 22952-26001 study. J Clin Oncol 2011; 29: 134-141
• 273 Brown PD, Jaeckle K, Ballman KV. et al. Effect of Radiosurgery Alone vs. Radiosurgery With Whole Brain Radiation Therapy on Cognitive Function in Patients With 1 to 3 Brain Metastases: A Randomized Clinical Trial. JAMA 2016; 316: 401-409
• 274 Li XP, Meng ZQ, Guo WJ. et al. Treatment for liver metastases from breast cancer: results and prognostic factors. World J Gastroenterol 2005; 11: 3782-3787
• 275 Mariani P, Servois V, De Rycke Y. et al. Liver metastases from breast cancer: Surgical resection or not? A case-matched control study in highly selected patients. Eur J Surg Oncol 2013; 39: 1377-1383
• 276 Taşçi Y, Aksoy E, Taşkın HE. et al. A comparison of laparoscopic radiofrequency ablation versus systemic therapy alone in the treatment of breast cancer metastasis to the liver. HPB (Oxford) 2013; 15: 789-793
• 277 Fairhurst K, Leopardi L, Satyadas T. et al. The safety and effectiveness of liver resection for breast cancer liver metastases: A systematic review. Breast 2016; 30: 175-184
• 278 Sadot E, Lee SY, Sofocleous CT. et al. Hepatic Resection or Ablation for Isolated Breast Cancer Liver Metastasis: A Case-control Study With Comparison to Medically Treated Patients. Ann Surg 2016; 264: 147-154
• 279 Ruiz A, Wicherts DA, Sebagh M. et al. Predictive Profile-Nomogram for Liver Resection for Breast Cancer Metastases: An Aggressive Approach with Promising Results. Ann Surg Oncol 2017; 24: 535-545
• 280 Ruiz A, Castro-Benitez C, Sebagh M. et al. Repeat Hepatectomy for Breast Cancer Liver Metastases. Ann Surg Oncol 2015; 22 (Suppl. 03) S1057-S1066
• 281 Zhou JH, Rosen D, Andreou A. et al. Residual tumor thickness at the tumor-normal tissue interface predicts the recurrence-free survival in patients with liver metastasis of breast cancer. Ann Diagn Pathol 2014; 18: 266-270
• 282 Polistina F, Costantin G, Febbraro A. et al. Aggressive treatment for hepatic metastases from breast cancer: results from a single center. World J Surg 2013; 37: 1322-1332
• 283 van Walsum GA, de Ridder JA, Verhoef C. et al. Resection of liver metastases in patients with breast cancer: survival and prognostic factors. Eur J Surg Oncol 2012; 38: 910-917
• 284 Abbott DE, Brouquet A, Mittendorf EA. et al. Resection of liver metastases from breast cancer: estrogen receptor status and response to chemotherapy before metastasectomy define outcome. Surgery 2012; 151: 710-716
• 285 Spolverato G, Vitale A, Bagante F. et al. Liver Resection for Breast Cancer Liver Metastases: A Cost-utility Analysis. Ann Surg 2017; 265: 792-799 doi:10.1097/SLA.0000000000001715
• 286 Fan J, Chen D, Du H. et al. Prognostic factors for resection of isolated pulmonary metastases in breast cancer patients: a systematic review and meta-analysis. J Thorac Dis 2015; 7: 1441-1451
• 287 Meimarakis G, Rüttinger D, Stemmler J. et al. Prolonged overall survival after pulmonary metastasectomy in patients with breast cancer. Ann Thorac Surg 2013; 95: 1170-1180
• 288 Kycler W, Laski P. Surgical approach to pulmonary metastases from breast cancer. Breast J 2012; 18: 52-57
• 289 García-Yuste M, Cassivi S, Paleru C. Pulmonary metastasectomy in breast cancer. J Thorac Oncol 2010; 5: S170-S171
• 290 Yhim HY, Han SW, Oh DY. et al. Prognostic factors for recurrent breast cancer patients with an isolated, limited number of lung metastases and implications for pulmonary metastasectomy. Cancer 2010; 116: 2890-2901
• 291 Clive AO, Jones HE, Bhatnagar R. et al. Interventions for the management of malignant pleural effusions: a network meta-analysis. Cochrane Database Syst Rev 2016; (05) CD010529